Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 3/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL477621 | 0.80 | ACP3 (0.61) | ACP3TSHRGAAMAPK1ALDH1A1 | |
| SCHEMBL477389 | 0.80 | ACP3 (0.61) | ACP3TSHRGAAMAPK1ALDH1A1 | |
| SCHEMBL477466 | 0.80 | ACP3 (0.61) | ACP3TSHRGAAMAPK1ALDH1A1 | |
| SCHEMBL13295537 | 0.76 | SLC2A1 (0.61) | ACP3NR3C1PGRNR3C2AR | |
| SCHEMBL34971 | 0.76 | SLC2A1 (0.61) | ACP3NR3C1PGRNR3C2AR | |
| SCHEMBL40557 | 0.76 | SLC2A1 (0.61) | ACP3NR3C1PGRNR3C2AR | |
| SCHEMBL13295535 | 0.76 | SLC2A1 (0.61) | ACP3NR3C1PGRNR3C2AR | |
| SCHEMBL13295540 | 0.76 | SLC2A1 (0.61) | ACP3NR3C1PGRNR3C2AR | |
| SCHEMBL14205685 | 0.76 | SLC2A1 (0.61) | ACP3NR3C1PGRNR3C2AR | |
| SCHEMBL439140 | 0.75 | MLKL (0.41) | TSHRGAAALDH1A1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129520-B2 | Methods and intermediates for the synthesis of dipyrrin-substituted porphyrinic macrocycles | NORTH CAROLINA STATE UNIVERSITY (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110197969-A1 | METHODS AND INTERMEDIATES FOR THE SYNTHESIS OF DIPYRRIN-SUBSTITUTED PORPHYRINIC MACROCYCLES | UNITED STATES DEPARTMENT OF ENERGY | 2011-08-18 | — | — | US | disclosed |
| US-7947828-B2 | Methods and intermediates for the synthesis of dipyrrin-substituted porphyrinic macrocycles | NORTH CAROLINA STATE UNIVERSITY (US) | 2011-05-24 | — | — | US | disclosed |
| US-20100200066-A1 | METHODS AND INTERMEDIATES FOR THE SYNTHESIS OF DIPYRRIN-SUBSTITUTED PORPHYRINIC MACROCYCLES | UNITED STATE DEPARTMENT OF ENERGY | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100200066-A1 | METHODS AND INTERMEDIATES FOR THE SYNTHESIS OF DIPYRRIN-SUBSTITUTED PORPHYRINIC MACROCYCLES | HCCS, PPOX, DHPS | ACP3 3864/4885NR3C1 3827/4885PGR 3825/4885 |
| US-20110197969-A1 | METHODS AND INTERMEDIATES FOR THE SYNTHESIS OF DIPYRRIN-SUBSTITUTED PORPHYRINIC MACROCYCLES | HCCS, PPOX, DHPS | ACP3 3864/4885NR3C1 3827/4885PGR 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.